Each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.
Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. The company has developed a proprietary database of protein sequences based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company’s team that consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s.
The unrivaled experience of the BioXpress team also allows to define analytical packages to be implemented at the different stages of each biosimilar development.
Finally, the originator database is constantly updated with newly acquired originator samples sourced from different regions and continuously compared to our own biosimilars.
We believe that this is the only way to ensure biosimilarity to the originator in terms of efficacy and safety.